Brief: Ultimovacs Q2 Operating Expenses NOK 45.3 Million
21/08/2024 06:00
Aug 21 (Reuters) - Ultimovacs Q2 operating cash flow NOK -50.5 million
Recent news on Zelluna ASA
See all newsNorway's Zelluna ASA reports Q2 loss
Brief: Zelluna Reports Q2 Total Loss Of NOK 19.7 Million
Brief: Zelluna Says IDMC Recommends Recruitment Of Next Two Patients At First Dose Level
Brief: Zelluna Says First Patient Dosed With Zi-Ma4-1 In Zima-101 Phase 1 Trial
Brief: Zelluna Wins NOK 16 Mln Research Council Of Norway Grant